Adding PD-1/PD-L1 Inhibitors to Chemotherapy for the First-Line Treatment of Extensive Stage Small Cell Lung Cancer (SCLC): A Meta-Analysis of Randomized Trials
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Adding PD-1/PD-L1 Inhibitors to Chemotherapy for the First-Line Treatment of Extensive Stage Small Cell Lung Cancer (SCLC): A Meta-Analysis of Randomized Trials
Authors
Keywords
-
Journal
Cancers
Volume 12, Issue 9, Pages 2645
Publisher
MDPI AG
Online
2020-09-16
DOI
10.3390/cancers12092645
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Treatment patterns and survival outcomes for small-cell lung cancer patients – a Swedish single center cohort study
- (2020) Salomon Tendler et al. ACTA ONCOLOGICA
- Safety and patient-reported outcomes of atezolizumab, carboplatin, and etoposide in extensive-stage small-cell lung cancer (IMpower133): a randomized phase I/III trial
- (2020) A.S. Mansfield et al. ANNALS OF ONCOLOGY
- Real‐world treatment patterns and outcomes of patients with extensive disease small cell lung cancer
- (2020) Christine M. Cramer‐van der Welle et al. EUROPEAN JOURNAL OF CANCER CARE
- Durvalumab ± tremelimumab + platinum-etoposide in first-line extensive-stage SCLC (ES-SCLC): Updated results from the phase III CASPIAN study.
- (2020) Luis G. Paz-Ares et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized phase II clinical trial of cisplatin/carboplatin and etoposide (CE) alone or in combination with nivolumab as frontline therapy for extensive-stage small cell lung cancer (ES-SCLC): ECOG-ACRIN EA5161.
- (2020) Ticiana Leal et al. JOURNAL OF CLINICAL ONCOLOGY
- KEYNOTE-604: Pembrolizumab (pembro) or placebo plus etoposide and platinum (EP) as first-line therapy for extensive-stage (ES) small-cell lung cancer (SCLC).
- (2020) Charles M. Rudin et al. JOURNAL OF CLINICAL ONCOLOGY
- Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study
- (2020) Charles M. Rudin et al. JOURNAL OF CLINICAL ONCOLOGY
- Use of targeted next generation sequencing to characterize tumor mutational burden and efficacy of immune checkpoint inhibition in small cell lung cancer
- (2019) Biagio Ricciuti et al. Journal for ImmunoTherapy of Cancer
- A Randomized Non-Comparative Phase 2 Study of Anti-Programmed Cell Death-Ligand 1 Atezolizumab or Chemotherapy as Second-Line Therapy in Patients with Small Cell Lung Cancer: Results from the IFCT-1603 Trial
- (2019) Jean-Louis Pujol et al. Journal of Thoracic Oncology
- Role of thoracic consolidation radiation in extensive stage small cell lung cancer: A systematic review and meta-analysis of randomised controlled trials
- (2019) Shrinivas Rathod et al. EUROPEAN JOURNAL OF CANCER
- Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer
- (2019) Matthew D. Hellmann et al. CANCER CELL
- Treatment and outcome of 432 patients with extensive-stage small cell lung cancer in first, second and third line – Results from the prospective German TLK cohort study
- (2019) Claus-Christoph Steffens et al. LUNG CANCER
- Challenging the recalcitrant disease—developing molecularly driven treatments for small cell lung cancer
- (2019) Daisy W.S. Mak et al. EUROPEAN JOURNAL OF CANCER
- Fatal adverse events in two thymoma patients treated with anti-PD-1 immune check point inhibitor and literature review
- (2019) Thomopoulou Konstantina et al. LUNG CANCER
- 1736OIMpower133: Updated overall survival (OS) analysis of first-line (1L) atezolizumab (atezo) + carboplatin + etoposide in extensive-stage SCLC (ES-SCLC)
- (2019) M Reck et al. ANNALS OF ONCOLOGY
- Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial
- (2019) Luis Paz-Ares et al. LANCET
- Pembrolizumab After Two or More Lines of Previous Therapy in Patients With Recurrent or Metastatic SCLC: Results From the KEYNOTE-028 and KEYNOTE-158 Studies
- (2019) Hyun Cheol Chung et al. Journal of Thoracic Oncology
- The Role of Prophylactic Cranial Irradiation in Patients With Extensive Stage Small Cell Lung Cancer: A Systematic Review and Meta-Analysis
- (2018) Chi Hoon Maeng et al. Journal of Thoracic Oncology
- Phase II Study of Maintenance Pembrolizumab in Patients with Extensive-Stage Small Cell Lung Cancer (SCLC)
- (2018) Shirish M. Gadgeel et al. Journal of Thoracic Oncology
- Do immune checkpoint inhibitors need new studies methodology?
- (2018) Roberto Ferrara et al. Journal of Thoracic Disease
- Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non–Small-Cell Lung Cancer
- (2018) Kathryn C. Arbour et al. JOURNAL OF CLINICAL ONCOLOGY
- First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
- (2018) Leora Horn et al. NEW ENGLAND JOURNAL OF MEDICINE
- LBA5Efficacy and safety of nivolumab (nivo) monotherapy versus chemotherapy (chemo) in recurrent small cell lung cancer (SCLC): Results from CheckMate 331
- (2018) M Reck et al. ANNALS OF ONCOLOGY
- Third-Line Nivolumab Monotherapy in Recurrent SCLC: CheckMate 032
- (2018) Neal Ready et al. Journal of Thoracic Oncology
- Italian, Multicenter, Phase III, Randomized Study of Cisplatin Plus Etoposide With or Without Bevacizumab as First-Line Treatment in Extensive-Disease Small-Cell Lung Cancer: The GOIRC-AIFA FARM6PMFJM Trial
- (2017) Marcello Tiseo et al. JOURNAL OF CLINICAL ONCOLOGY
- Moving Immune Checkpoint Blockade in Thoracic Tumors beyond NSCLC
- (2016) Francesco Facchinetti et al. Journal of Thoracic Oncology
- Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial
- (2016) Scott J Antonia et al. LANCET ONCOLOGY
- PD-L1 expression in small cell neuroendocrine carcinomas
- (2015) Anne M. Schultheis et al. EUROPEAN JOURNAL OF CANCER
- Signatures of mutational processes in human cancer
- (2013) Ludmil B. Alexandrov et al. NATURE
- Carboplatin- or Cisplatin-Based Chemotherapy in First-Line Treatment of Small-Cell Lung Cancer: The COCIS Meta-Analysis of Individual Patient Data
- (2012) Antonio Rossi et al. JOURNAL OF CLINICAL ONCOLOGY
- A Systematic Analysis of Efficacy of Second-Line Chemotherapy in Sensitive and Refractory Small-Cell Lung Cancer
- (2012) Taofeek K. Owonikoko et al. Journal of Thoracic Oncology
- Small-cell lung cancer
- (2011) Jan P van Meerbeeck et al. LANCET
- Maintenance or consolidation therapy in small-cell lung cancer: A systematic review and meta-analysis
- (2010) Antonio Rossi et al. LUNG CANCER
- Paraneoplastic Syndromes: An Approach to Diagnosis and Treatment
- (2010) Lorraine C. Pelosof et al. MAYO CLINIC PROCEEDINGS
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started